Results 141 to 150 of about 26,259 (260)

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. [PDF]

Cells
Maher N, Al Deeban B, Diop NM, Assaf J, Moia R, Mouhssine S, Gaidano G.   +6 more
europepmc   +1 more source

Physical Activity and Sedentary Behaviour in Children With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Physical activity (PA) is vital in child development, while inactivity remains a leading contributor to global mortality. Therapeutic advances have enabled greater PA in boys with haemophilia (BwH), yet robust UK data on objectively measured PA and sedentary behaviour (SB) across severities are limited.
Melanie Bladen, Lucy Alderson, Eleanor Main, Mario Cortina‐Borja   +3 more
wiley   +1 more source

Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy. [PDF]

Mol Cancer
Battistini E, Lapuhs P, Jiménez A, Garrido-Areal S, Rivas-Gómez L, Zagorac I, Álvarez-Vallina L, Alonso MJ, Sanjurjo L.   +8 more
europepmc   +1 more source

Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease ...
Masahiro Takeyama, Atsuki Yamashita, Tomoko Yamaguchi, Takahiro Ito, Yui Sugawara, Akiko Ioka, Tazuko Tokugawa   +6 more
wiley   +1 more source

The XX Factor in Hemophilia: Diagnostic, Therapeutic, and Research Gaps for Women and Girls

Haemophilia, EarlyView.
ABSTRACT Introduction Hemophilia has traditionally been viewed as an X‐linked disorder affecting men and boys, with women and girls labeled as “carriers”, presumed to be clinically unaffected. This paradigm has contributed to under‐recognition, delayed diagnosis, and undertreatment of females with hemophilia‐associated genotypes despite an increasingly
Kelsey Uminski, Ellen Cusano
wiley   +1 more source

Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity. [PDF]

Sci Adv
Kschonsak YT, Liang WC, Chan J, Kan D, Nguyen T, Ruiz K, Kee YS, Tsai WK, Xi H, Moskalenko M, Morgenstern T, Herault A, Cabon L, Okuda R, Stawicki SS, Chan J, Grimmer M, Ellerman D, Mondo J, Ruff CF, Schaefer G, Segal U, Piskol R, Agard NJ, Comps-Agrar L, de Sousa E Melo F, Koerber JT.   +26 more
europepmc   +1 more source

BLIMP‐1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses

Immunology &Cell Biology, EarlyView.
This study found that BLIMP‐1 is highly expressed in activated effector/memory human regulatory T cells, especially CD39+ Tregs, where it is associated with increased IL‐10 production and a conserved phenotype across blood and lung tissues during immune responses such as SARS‐CoV‐2 infection.
Chansavath Phetsouphanh, Laura Cook, Katherine J. L. Jackson, Deirdre Cuff, Vera Klemm, Bikash Manandhar, Denise C. Hsu, Yin Xu, John J. Zaunders, Anthony D. Kelleher, Nabila Seddiki   +10 more
wiley   +1 more source

T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges. [PDF]

Cell Rep Med
Paczesny S, Barwe SP, Gopalakrishnapillai A, Cheung NV.   +3 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source